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Abstract
Background: Depression is common among patients with axial spondyloarthritis (axSpA), but reports of its prevalence
are highly variable. We performed a systematic review to (i) describe the prevalence of depression in axSpA, (ii)
compare its prevalence between axSpA, ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) cohorts,
and (iii) compare disease activity and functional impairment between those with and without depression.
Methods: We searched Medline, PubMed, Web of Science, PsycINFO, CINAHL Plus, the Cochrane library and
conference abstracts of the European League Against Rheumatism, British Society for Rheumatology and American
College of Rheumatology using a predefined protocol in accordance with Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) guidelines. Meta-analysis was performed using quality-effects model.
Results: Fifteen original articles and one abstract were included for analysis; 14 studies described AS cohorts and two nr-
axSpA. Three screening criteria and one diagnostic criterion were used to define depression. Prevalence ranged from 11
to 64% depending on criteria and thresholds used. Pooled prevalence of at least moderate depression was 15% using the
Hospital Anxiety and Depression Scale (HADS) threshold of ≥ 11. The prevalence of depression was similar between
axSpA, AS and nr-axSpA cohorts. Patients with depression had significantly worse disease activity, including higher
BASDAI by 1.4 units (95% CI 1.0 to 1.9), ASDAS by 0.5 units (95% CI 0.3 to 0.7) and ESR by 3.5 mm/h (95% CI 0.6 to 6.4).
They also had greater functional impairment with higher BASFI and BASMI by 1.2 units (95% CI 0.6 to 1.8) and 0.6 units
(95% CI 0.3 to 0.8), respectively. Mean age of each study cohort inversely correlated with depression prevalence.
Conclusions: Depression is common among axSpA patients and is associated with more severe disease activity and
functional impairment. Identifying and managing depression should form part of their holistic care. Further longitudinal
studies are needed to explore the impact of depression on treatment outcomes and axSpA treatment on symptoms of
depression.
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Background
Axial spondyloarthritis (axSpA) is a chronic inflammatory
disease which predominantly affects the axial skeleton. It
can be divided into ‘radiographic’ (ankylosing spondylitis,
AS) and ‘non-radiographic’ (nr-axSpA), depending on
whether definitive structural changes are evident on plain
radiographs of sacroiliac joints [1, 2]. They are both charac-
terised by inflammatory pain and functional impairment [3].
Like other conditions for which chronic pain is a feature,
axSpA is known to be associated with depression [4, 5].
However, quantifying the prevalence of depression is chal-
lenging. Formal diagnosis of depression requires expertise
and time consuming assessments. Instead, screening ques-
tionnaires are often used in both clinical and research
settings. There are many different screening tools, each
with variable score thresholds to define depression.
Estimating the prevalence of depression in axSpA is fur-
ther complicated by the distinction of AS and nr-axSpA.
Although they can be considered entities along a spectrum,
there are key differences: the proportion of male patients is
higher in AS than nr-axSpA cohorts, functional impairment
is greater in AS cohorts, and AS is more commonly associ-
ated with elevated inflammatory markers [6]. Gender, func-
tional impairment and inflammation can all potentially
influence the likelihood of developing depression [7–9].
In spite of these challenges, quantifying the prevalence
of depression is an important first-step to improve
awareness and management of this comorbidity. Depres-
sion has direct importance to rheumatologists since
current methods of disease severity assessments, on
which important treatment decisions are made, rely on
subjective patient-reported measures, such as the Bath
AS Disease Activity Index (BASDAI) and spinal pain vis-
ual analogue scale (spVAS). The presence of depression
is known to influence the reporting of pain and impair-
ment [5]. Equally, more severe disease likely increases
the risk of developing depression. It has been shown that
self-reported anxiety and depression in axSpA have
greater associations with disease activity and functional
impairment than smoking or deprivation [10].
To date, depression in axSpA has not been systematic-
ally reviewed. Our aims were therefore to (i) report
pooled prevalence of depression in axSpA, (ii) compare
the prevalence of depression between axSpA, AS and
nr-axSpA groups, and (iii) compare disease activity and
functional impairment between those with and without
comorbid depression.
Patients and methods
A systematic review was performed in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [11]. The protocol
for this review was pre-registered in advance (PROSPERO:
CRD42017082359). Two reviewers (SZ, DT) searched
Medline, PubMed, Web of Science, PsycINFO, CINAHL
plus and the Cochrane Library for relevant literature in
February 2018. In addition, abstract archives of the European
League Against Rheumatism (EULAR), British Society for
Rheumatology (BSR) and American College of Rheuma-
tology (ACR) were searched up to, and including, 2017.
The following search term was used: depress* AND (anky-
losing OR spondyloarthr*). Differential nomenclature for
depression (affective disorder, mood disorder, adjustment
disorder, dysthymia) did not affect results in preliminary
searches.
Studies were included if they: (i) were cross-sectional
in design or were longitudinal studies reporting baseline
data, (ii) used a validated diagnostic or screening criteria
for depression with a defined cut-off threshold, and (iii)
recruited adult patients fulfilling the modified New York
or ASAS criteria for AS or axSpA, respectively. Studies
were excluded if they used non-representative sampling
(highly selective recruitment criteria, for example, stud-
ies that only recruited women) or had a samples size of
less than 30 (to avoid unreliable prevalence estimates).
Publications in abstract form only were also considered,
as some prevalence studies may not be published as full
articles and may have sufficiently described methodology
within the restrictions of an abstract. Reviews, com-
ments and editorials were excluded.
Two reviewers (DT, NM) independently assessed study
eligibility and extracted data from qualifying studies. Any
discrepancies were resolved through discussion moderated
by a third reviewer. Information from included studies
was extracted into predefined tabulated summaries con-
taining data on: depression criteria and threshold used,
study design, sample size, country setting, mean age, per-
centage of males, and depression prevalence.
Studies were assessed for risk of bias (SZ, NM) using
the Health States Quality Index (Additional file 1:
Table S1). This is an 11-point scoring system that assesses
studies under the following headings: target population and
observation period, diagnostic criteria, case ascertainment,
measurement administration, catchment area and prevalence
measure [12]. For purposes of the below meta-analysis, the
score was divided by 10 to derive a quality parameter with
an upper limit of 1.
Statistical analysis
Prevalence estimates were reported as percentages (95%
confidence interval (CI), I2 statistic). When performing
meta-analysis of proportions (variable bound between 0
and 1), traditional weighting methods based on inverse
variance are problematic when the proportions are close
to the bound limits, giving more weight to such studies
[13]. The double arcsine transformation was therefore
used. Results were pooled according to depression cri-
teria and threshold using quality-effects models. This
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method redistributes weights by accounting for the
above quality parameter and can be considered as an
extension of the random-effects model. Sub-group
meta-analyses by diagnostic category were also per-
formed. All estimates were also presented using
random-effects models (DerSimonian-Laird). Heterogen-
eity of meta-analysis estimates were presented using the
I2 statistic. Funnel plot and the Doi plot/LFK index [13]
were used to assess risk of publication bias.
Commonly used thresholds for each screening tool
were used to categorise severity of depression. For the
Hospital Anxiety and Depression Scale depression sub-
scale (HADS) ≤ 7 was interpreted as no depression, 8 to
10 mild, 11 to 14 moderate and ≥ 15 severe [14]. For the
Zung Self-Rating Depression Scale (SDS) ≤ 49 was inter-
preted as no depression, 50 to 69 depression, ≥ 70 severe
depression [15]. The Patient Health Questionnaire
(PHQ-9) threshold for depression has been suggested to
be between 8 and 11, depending on context [16]. Studies
that used similar thresholds were grouped together. If a
study reported depression prevalence using two different
thresholds, it could contribute to more than one pooled
estimate. Sensitivity analyses were performed: studies
reporting outlying prevalence estimates were critically
reviewed and, if appropriate, excluded to evaluate
changes in prevalence and heterogeneity. The associ-
ation between study characteristics and reported depres-
sion prevalence was assessed using Spearman’s rank
correlation (rs).
Differences in markers of disease activity and functional
impairment were compared between groups with and
without depression. Weighted mean difference (WMD)
was calculated for each marker of disease activity and func-
tional impairment, with pooled estimates shown in forest
plots. Analyses were performed using MetaXL version 5.3
(Sunrise Beach, Australia; http://www.epigear.com/).
Results
A total of 769 full-text publications and 40 conference
abstracts were found from the literature search. These ti-
tles and abstracts were screened for eligibility. After ex-
cluding duplicates and irrelevant studies, 70 studies were
assessed for full-text eligibility, from which 15 full-text
articles [17–31] and one abstract [32] were included in the
analysis. Among the excluded studies, two [33, 34] used
the same cohort as the study by Healey et al. [20] and two
[35, 36] reported the same cohort as Hakkou et al. [26]. A
summary of the selection process is shown in the flow-
chart (Additional file 1: Figure S1).
Of the 16 included studies, 14 recruited participants
with AS (including three axSpA studies which reported on
AS participants separately) and two reported on nr-axSpA
cohorts (including one axSpA study which reported on
nr-axSpA participants separately). Sample size ranged
from 60 to 1504. A total of 4753 axSpA patients were in-
cluded across all studies, including separately described
groups of 2857 AS and 334 nr-axSpA patients. Twelve
studies were cross-sectional in design, three were lon-
gitudinal, and one was a randomised controlled trial
(RCT). Four studies were from Turkey, five from
China (including one from Hong Kong), three from
the UK, and one each from Greece, Morocco and
Spain (Canary Islands). The RCT recruited from Europe,
Asia and South America.
Three screening criteria and one diagnostic criterion
were used for identifying depression. Nine studies used
HADS with three different thresholds, five used SDS with
three different thresholds, and one used PHQ-9. For the
purposes of meta-analyses, HADS ≥ 7/8 were grouped to-
gether, and SDS ≥ 50/51/53 were grouped together. Only
one study used diagnostic criteria for depression, the
Structured Clinical Interview for Diagnostic and Statistical
Manual of Mental Disorders (SCID).
Given the strict inclusion criteria employed for this
meta-analysis, most studies had high quality scores with
one scoring 6, three scoring 8, nine scoring 9 and three
scoring ≥ 10 on the Health States Quality Index
(Additional file 1: Table S2).
Prevalence of depression
The prevalence of depression ranged from 11 to 64%,
depending on criteria and threshold used to identifying
disease. Table 1 summarises the study characteristics,
depression prevalence and quality score. Funnel/Doi
plots and the LFK index suggested no evidence of publi-
cation bias (Additional file 1: Figure S2).
Figure 1 shows a forest plot of prevalence estimates
using quality-effects models, grouped by criteria and
threshold. Pooled prevalence of mild depression (HADS
≥ 7/8) was 38% (95% CI 30 to 45%, I2 = 85%). Pooled
prevalence of at least moderate depression, using HADS
≥ 11, was 15% (95% CI 6 to 25%, I2 = 89%) and using
SDS was 52% (95% CI 29 to 75%, I2 = 96%). The study by
Hyphantis et al. [19] reported 15% depression using
PHQ9 ≥ 10. The study by Chan et al. [24] reported a
prevalence of 11% for major depressive disorder using the
SCID reported. Pooled prevalence using both quality- and
random-effects meta-analysis are shown in Table 2.
Two studies reported disproportionately high preva-
lence of depression. Hakkou et al. [26] attributed this to
the cohort’s low socioeconomic status. Excluding this
study improved the HADS subgroup heterogeneity with-
out altering the pooled estimates significantly (Table 2).
The Chinese study by Jiang et al. [31] reported the highest
depression prevalence (64%). This cohort had the lowest
mean age (27 years) and reported a low participation rate,
with only 25% (683/2772) of the total cohort completing
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the required assessments. Excluding this study reduced
both heterogeneity and prevalence estimate (52 to 36%)
for the SDS group.
Prevalence of depression was inversely associated with
age (rs =− 0.71, P = 0.003) but not with study size, BASDAI,
year of publication or proportion of males (data not shown).
Comparing axSpA, AS and nr-axSpA cohorts
Fourteen of 16 included studies reported the prevalence
of depression for AS cohorts. The pooled prevalences
for AS cohorts are shown in Table 2. Again, the studies
by Hakkou et al. and Jiang et al. reported high preva-
lence of depression (Additional file 1: Figure S3) and
were excluded in sensitivity analyses.
The studies by Chan et al. [24], Zou et al. [28] and
Kilic et al. [18] reported similar prevalence of depres-
sion between axSpA and their AS subgroups (Table 1).
Kilic et al. also reported similar prevalence between
AS and nr-axSpA subgroups (45.4 vs 42.3%, P = 0.58).
Two studies reported depression prevalence for
nr-axSpA cohorts. Pooled prevalence of mild depression
(HADS ≥ 7/8) for nr-axSpA was similar to that of AS co-
horts (Table 2).
Comparing markers of disease severity between groups
with and without depression
Eight studies compared markers of disease severity between
groups with and without depression (Additional file 1:
Table 1 Summary of study characteristics, prevalence of depression and quality of studies included in this meta-analysis
Depression criteria
(threshold)
Study Study design Diagnosis Sample size Country Age, mean (SD) Males, % Depression
prevalence, %
Quality
index
HADS (≥ 7) Baysal 2011 [27] Cross-sectional AS 243 Turkey 34.7 (10.4) 86.4 39.5 0.8
Kilic 2014 [18] Cross-sectional axSpA 316 Turkey 36.3 (9.5) 63.0 44.0 0.9
AS 174 38.3 (NS) NS 45.4
nr-axSpA 142 33.9 (NS) NS 42.3
HADS (≥ 8) Healey 2011 [20] Cross-sectional AS 612 UK 50.8 (12.2) 71.6 32.0 1.0
Hakkou (a)
2011 [26]
Cross-sectional AS 110 Morocco 38.5 (12.6) 68.2 55.5 0.9
Ates 2015 [32] Cross-sectional AS 60 Turkey NS 66.7 43.3 0.7
Dougados (a)
2017 [25]
RCT nr-axSpA 192 Europe, Asia,
and
South America
31.9 (7.8) 60.1 32.3 0.9
HADS (≥ 11) Martindale
2006 [21]
Longitudinal AS 89 UK Median (IQR):
50 (38.5–55.5)
83.1 12.4 0.9
MacFarlane 2017
[30]
Longitudinal axSpA 1504 UK Median (IQR):
51.2 (40.1–63.1)
68 13.8 1.0
Hakkou (b)
2011 [26]
Cross-sectional AS 110 Morocco 38.5 (12.6) 68.2 37.3 0.9
Rodríguez-Lozano
2012 [29]
Cross-sectional AS 190 Spain 48.4 (11.7) 75.3 10.5 0.9
Dougados (b)
2017 [25]
Cross-sectional nr-axSpA 192 Europe, Asia,
and
South America
31.9 (7.8) 60.1 15.6 0.9
SDS (≥ 50) Günaydin
2009 [23]
Cross-sectional AS 62 Turkey 39.6 (10.3) 83.9 27.4 0.9
Jiang 2018 [31] Cross-sectional AS 683 China 27.3 (8.7) 80.4 64.0 1.0
SDS (≥ 51) Zhang 2016 [17] Cross-sectional AS 314 China 27.6 (8.3) 74.5 35.4 0.8
SDS (≥ 53) Xu 2016 [22] Cross-sectional AS 103 China 32.9 (10.7) 75.7 36.9 0.8
Zou 2016 [28] Cross-sectional axSpA 60 China 31.8 (10.1) 73.3 43.3 0.8
AS 40 31.5 (10.1) 70.0 42.5
PHQ-9 (≥ 10) Hyphantis
2013 [19]
Longitudinal AS 55 Greece 42.9 (10.9) 85.5 14.5 0.9
SCID Chan 2017 [24] Cross-sectional axSpA 160 Hong Kong 46.2 (12.7) 70.6 10.6 0.9
AS 122 NS NS 11.5
HADS Hospital Anxiety and Depression Scale—depression subscale, SDS Zung self-rating depression scale, PHQ9 Patient Health Questionnaire, SCID Structured
Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, AS ankylosing spondylitis, axSpA axial spondyloarthritis, nr-axSpA non-radiographic
axSpA, NS not specified, IQR interquartile range
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Fig. 1 Pooled prevalence of depression in axSpA cohorts, grouped by criteria and threshold
Table 2 Summaries of pooled depression prevalence grouped by screening criteria and thresholds used
Quality-effects model Random-effects model Sensitivity analysis
Pooled prevalence 95% CI, I2 Pooled prevalence 95% CI, I2 Pooled prevalence 95% CI, I2
All studies HADS (≥ 7/8) 38% 30 to 45%, I2 = 85% 40% 47 to 33%, I2 = 85% 36% 30 to 42%, I2 = 77%
HADS (≥ 11) 15% 6 to 25%, I2 = 89% 17% 11 to 24%, I2 = 89% 14% 12 to 15%, I2 = 0%
SDS 52% 29 to 75%, I2 = 96% 41% 26 to 58%, I2 = 96% 36% 31 to 40%, I2 = 13%
AS HADS (≥ 7/8) 38% 28 to 48%, I2 = 86% 38% 28 to 48%, I2 = 86% 36% 28 to 45%, I2 = 79%
HADS (≥ 11) 18% 3 to 36%, I2 = 94% 18% 3 to 36%, I2 = 94% 11% 8 to 15%, I2 = 0%
SDS 52% 28 to 76%, I2 = 96% 41% 25 to 58%, I2 = 96% 35% 31 to 39%, I2 = 0%
nr-axSpA HADS (≥ 7/8) 36% 27 to 46%, I2 = 71% 36% 27 to 46%, I2 = 71% NA NA
Estimates were presented by quality-effects model, random-effects model, and sensitivity analysis excluding the studies by Hakkou et al. and Jiang et al.
HADS Hospital Anxiety and Depression Scale—depression subscale, SDS Zung self-rating depression scale, AS ankylosing spondylitis, axSpA axial spondyloarthritis,
nr-axSpA non-radiographic axSpA, NA not applicable
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Table S3). For BASDAI, spVAS and BASFI, most studies
reported significantly higher scores in the group with
depression compared to those without, regardless of criteria
or threshold used to define depression (Fig. 2). Across the
depressed groups, scores were generally worse for the Bath
AS metrology index (BASMI), AS disease activity score
(ASDAS), CRP and ESR, but few individual comparisons
were statistically significant.
All eight studies reported significantly worse BASDAI in
the group with depression. Despite the variety of criteria
and thresholds used, the weighted mean differences
(WMDs) were similar. Pooling WMDs, BASDAI was
1.4 units (95% CI 1.0 to 1.9) higher in the depressed
group. Of the six studies that reported spVAS, the groups
with depression scored 1.2 units (95% CI 0.7 to 1.7)
higher. Only two studies reported ASDAS, with a pooled
WMD of 0.5 units (95% CI 0.3 to 0.7) between the two
groups. ESR (3.5 mm/h, 95% CI 0.6 to 6.4 mm/h) was sig-
nificantly higher in groups with depression, but not CRP
(1.3 mg/dl, 95% CI − 0.9 to 3.4).
All studies reported significantly worse BASFI in the
group with depression. The pooled difference in BASFI
was 1.2 units (95% CI 0.6 to 1.8) but with more variation
among the studies. The group with depression in the study
by Hakkou et al. had much poorer function (BASFI,
BASMI) compared to depressed groups of other studies,
despite using a threshold for ‘mild’ depression. In contrast
to other Bath indices, not all studies reported a difference
in BASMI when comparing groups with and without de-
pression. Nevertheless, the pooled estimate showed that
axSpA patients with comorbid depression had significantly
higher BASMI than those without (0.6 units, 95% CI 0.3
to 0.8).
Discussion
This systematic review and meta-analysis of nearly five
thousand axSpA patients has shown that depression is
highly prevalent and associated with greater disease ac-
tivity and functional impairment. At least moderate de-
pression was found in 15% of patients, although
estimates varied depending on the criteria and thresh-
olds selected; pooled estimates of prevalence of depres-
sion in axSpA were 38 to 52% using lower HADS
thresholds and the SDS.
The strength of this meta-analysis lies in its strict in-
clusion criteria, as prevalence estimates can vary
Fig. 2 Measures of disease activity and functional impairment are worse in axial spondyloarthritis patients with comorbid depression. Effect sizes
shown as weighted mean difference (WMD)
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significantly depending on variable sampling methods
and definition for depression. The included studies had
high quality overall and low risk of publication bias.
However, overall heterogeneity of prevalence estimates
remained high, largely due to the wide range of screen-
ing or diagnostic tools used to define depression. Het-
erogeneity was improved when estimates were pooled by
depression definition, and further reduced in sensitivity
analyses excluding the studies by Hakkou et al. and Jiang
et al. These two studies highlight the importance of age,
which was inversely associated with depression preva-
lence, and socioeconomic status, which future studies
could approximate by grouping by continent or gross
domestic product.
The main limitation of the meta-analysis of prevalence
was that almost all studies used screening criteria to de-
tect depression. This may lead to over-estimation of the
prevalence of true depression. Using diagnostic criteria,
Chan et al. found one of the lowest prevalences of de-
pression. However, they reported a sensitivity and speci-
ficity of 82 and 79%, respectively, for HADS ≥ 8 in their
axSpA cohort, using SCID as the gold standard [24].
Almost all studies described hospital cohorts which are
likely to have more severe disease than a random or
primary care sample. However, disease activity was not
found to be associated with prevalence estimates;
although the RCT cohort had much higher disease activity
than observational cohorts, it reported similar prevalence
of depression. The higher disease activity and functional
impairment found in patients with depression were un-
adjusted for confounders such as smoking and deprivation.
It is possible that adjusted effect sizes could be smaller, al-
though data from our own axSpA cohort [10] found that
doing so made little difference to the effect size of depres-
sion. Lastly, the direction of the causal relationship between
depression and axSpA disease severity could only be specu-
lated from these studies of cross-sectional association.
The prevalence of depression in axSpA was higher
than that of the general population [37], but very similar
to those reported in rheumatoid arthritis (RA) cohorts.
A meta-analysis of RA patients reported depression in
15% using HADS ≥ 11 and 34% using HADS ≥ 8 [38].
This similarity was unexpected since the RA cohorts
were mostly female. Given that depression is more
prevalent in females in the general population [8], it is
possible that more male axSpA patients were reporting
depression than male RA patients. However, our finding
that the prevalence of depression was similar between
AS and nr-axSpA groups suggest that gender may not
be as significant a risk factor for depression in axSpA.
Patients with depression had significantly worse dis-
ease activity and functional impairment across most in-
dices. As an example, the pooled difference in BASDAI
was 1.4 units, which is clinically relevant as ≥ 2-unit
improvement is considered as response to TNF inhibi-
tors (TNFi) [39]. The direction of this potential causal rela-
tionship cannot be inferred from studies included in this
meta-analysis. Patients with more severe disease may be at
higher risk of developing comorbid depression. Conversely,
depression has been shown to exacerbate the perception of
pain [40] and may cause axSpA patients with depression to
report greater disease severity. This may explain why the
differences in subjective indices (BASDAI, spVAS, BASFI)
were larger than differences in objective measures (BASMI,
ASDAS). It is interesting that the difference in BASDAI
between groups with and without depression were similar
regardless of severity of depression; the presence of any
level of depression may adversely influence response to the
BASDAI questionnaire.
In healthcare systems where TNFi can only be continued
on the basis of demonstrable response, such as in the UK,
efforts should be made to identify and manage comorbid
depression to avoid withdrawing efficacious therapy in-
appropriately. More objective measures of disease activity,
such as ASDAS, may be more robust to the influence of de-
pression. Longitudinal axSpA studies are needed to evaluate
the impact of depression on treatment outcomes; we have
previously demonstrated, in a longitudinal RA cohort, that
depression at baseline adversely affects treatment outcomes
[41]. Equally, inflammation has been implicated in the
pathophysiology of depression and may contribute to
non-responsiveness to antidepressant therapies [9]. Longi-
tudinal studies could also shed light on whether TNFi im-
proves severity of depressive symptoms.
Conclusions
Depression is common among axSpA patients and is asso-
ciated with worse disease activity and functional impair-
ment. Clinicians should be mindful of comorbid depression
when managing axSpA patients, especially for younger pa-
tients and those with severe disease activity and functional
impairment. Patients with depression should be appropri-
ately referred and managed. This is especially pertinent if
depressive symptoms are thought to adversely influence as-
sessments of treatment response.
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